{"schema":"hottub-news/story/v1","story":"st_xc6kuintt6rj4xo6t3vq","title":"4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME","title_en":null,"outlets":1,"brief":null,"page":"https://hottub.news/stories/4dmt-advances-4d-150-into-phase-3-for-second-large-market-retina-xc6kuintt6","count":1,"items":[{"id":"n_xc6kuintt6rj4xo6t3vq","seq":419254,"kind":"press_release","title":"4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME","url":"https://www.globenewswire.com/news-release/2026/09/28/3369825/0/en/4dmt-advances-4d-150-into-phase-3-for-second-large-market-retina-indication-with-initiation-of-4sight-in-dme.html","summary":"EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic…","published":"2026-09-28T12:00:00Z","seen":"2026-09-28T12:07:22Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:fdmt","us35104e1001"],"entities":[{"id":"Q124433826","name":"4D Molecular Therapeutics, Inc.","type":"org"}],"mentions":2,"story":"st_xc6kuintt6rj4xo6t3vq","category":"science-technology","category_p":0.6200000047683716,"category2":"economy-business","sentiment":"neutral","tone":0.38999998569488525,"political":0.03999999910593033}]}